Octave® Bioscience, Inc. Announces Publication of Clinical Validation Study Results of its Novel, Multivariate Multiple Sclerosis Disease Activity (MSDA) Blood Test
The ongoing management of disease activity – the occurrence of new neurological symptoms and the rate of relapses – is a central theme of improving outcomes.
- The ongoing management of disease activity – the occurrence of new neurological symptoms and the rate of relapses – is a central theme of improving outcomes.
- Historically, however, there have been no dynamic, quantitative tools to measure disease activity over time.
- The test can be used throughout the course of a patient’s disease to enable more informed, actionable clinical decisions that will help with better disease management.
- “We are encouraged that these results validate the performance of the Octave MSDA Test and demonstrate its ability to quantitatively and objectively measure disease activity of patients with MS.